A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma
In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.
In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, a medical oncologist and chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.
During the Physician’s Education Resource® 18th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® held in January 2022, Postow spoke to a room of peers about this topic. His talk focused on the past, present, and future of BRAF-directed treatment. During the podcast discussion with host, Nichole Tucker of Targeted Oncology™, the discussion was expanding to dive into topics like; the efficacy of FDA-approve BRAF targeted therapies, the most recent FDA approval and its impact, exploring approved agents in new treatment settings, and other key druggable targets in melanoma.
During the talk, Postow also touches on the main clinical questions that oncologists still have about treating patients with BRAF-mutant melanoma and what research is aiming to provide answers in the near future.
Atlas Examines Tolerability of Hedgehog Pathway Inhibitors and Transition to IO in mBCC
October 16th 2024During a Case-Based Roundtable® event, Jennifer L. Atlas, MD, discussed treatment for a patient with basal cell carcinoma who reported challenging adverse events with hedgehog pathway inhibitor.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
